Akhil Shrivastava
Executive Vice President, Chief Financial OfficerEstée Lauder
CFOView Profile →Chief Financial Officer and Treasurer · 908 Devices
Chief Financial Officer and Treasurer of 908 Devices Inc. (Nasdaq: MASS), the Burlington, Massachusetts maker of handheld mass spectrometry and optical spectroscopy devices for chemical analysis at the point of need, a role he has held since March 2014. He was previously CFO of PerkinElmer's Life Sciences and Technology business unit and Chief Accounting Officer of Caliper Life Sciences, and is a licensed CPA.
Last reviewed: Sep 28, 2026
Chief Financial Officer and Treasurer 908 Devices
Last Reviewed: September 28, 2026
Joseph H. Griffith IV is Chief Financial Officer and Treasurer of 908 Devices, the Nasdaq-listed company based in Burlington, Massachusetts. It makes handheld devices that use mass spectrometry and optical spectroscopy to analyse chemicals at the point of need, in applications such as fentanyl and illicit drug detection, toxic exposure and security threats. He joined as CFO in March 2014, the same year the company launched its first device, and has stayed in the role through its public listing and a portfolio reshaping that took it out of desktop bioprocessing instruments. He spent the decade before that in finance at laboratory instrument companies, rising from controller to chief accounting officer at Caliper Life Sciences and then serving as a business unit CFO at PerkinElmer. He trained at Arthur Andersen and is a licensed CPA.
Griffith started his career in audit at Arthur Andersen, where he worked from August 1997 to February 2002. He then moved into corporate finance as Corporate Controller of Zymark Corporation, a maker of laboratory automation, robotics and liquid handling systems. When Caliper Life Sciences acquired Zymark in July 2003, he became Caliper’s Corporate Controller. He was promoted to Chief Accounting Officer and Vice President of Finance in April 2008. After PerkinElmer acquired Caliper, he served from November 2011 as Chief Financial Officer of PerkinElmer’s Life Sciences and Technology business unit.
In March 2014 he left to become Chief Financial Officer and Treasurer of 908 Devices, which was then developing its first handheld mass spectrometry device. According to its 10-K, the company has since sold more than 3,700 handheld devices to over 700 customers. In recent years it has narrowed its focus to handheld chemical detection for health, safety and defense customers. In March 2025 it sold its desktop portfolio to Repligen. In June 2025 it moved manufacturing from Boston to Danbury, Connecticut, and it cut its workforce by about 11%. In May 2026 it completed the acquisition of NIRLAB, a Swiss developer of near-infrared spectroscopy for instant material identification. The company reported total revenue of $56.2 million for 2025.
He remains CFO. The April 2026 proxy lists him as Chief Financial Officer and Treasurer, and he signed the company’s certification for the quarter ended 30 June 2026.
Villanova University
B.S., Accounting